2024年全球生命科学行业展望报告-变中求进 韧而有为

Investment Rating - The report maintains a cautiously optimistic outlook for the life sciences industry in 2024, anticipating a vibrant but cautious M&A and capital market environment [9]. Core Insights - Life sciences companies are focusing on disruptive trends such as rising pricing pressures, regulatory changes in the U.S., and the accelerated application of generative AI to enhance operational efficiency and patient outcomes [3][4]. - The global pharmaceutical market is projected to reach nearly $1.2 trillion in sales in 2024, indicating a recovery in pharmaceutical trade since Q3 2023 [4]. - The report emphasizes the importance of improving patient outcomes through personalized care and enhanced patient experiences, which are seen as critical for future growth [6]. Summary by Sections Exploring the Value of Generative AI and Emerging Technologies - Companies are exploring the potential of generative AI to reduce costs and increase revenues, with top biopharmaceutical firms potentially creating $5-7 billion in value through expanded AI deployment over five years [3]. - The integration of generative AI with digital transformation tools is expected to enhance efficiency across the life sciences value chain [3]. Global Drug Pricing Pressure - The report highlights the increasing global drug pricing pressures that are affecting R&D innovation, with governments expected to implement more regulatory measures in the second half of 2024 [4][6]. Accelerating R&D Value Realization - Companies are leveraging AI and generative AI to tackle complex biological challenges, accelerate drug discovery, and improve clinical trial experiences [3][10]. - The report notes that the pharmaceutical industry is expected to adjust strategies through strategic mergers and acquisitions to enhance revenue amidst patent expirations leading to over $200 billion in revenue loss [3][10]. Improving Patient Outcomes through Personalized Experiences - Life sciences companies are committed to enhancing patient experiences and outcomes, with executives identifying the need to improve patient engagement and trust as a primary action for 2024 [6][24]. - The report discusses the growing trend of personalized care and treatment support, which is expected to enhance patient journeys and outcomes [6]. M&A Activity and Market Dynamics - The report indicates that 2023 saw a strong performance in M&A activity within the life sciences sector, with 254 deals totaling $209.8 billion, surpassing 2022's figures [9][10]. - Major pharmaceutical companies are expected to continue utilizing M&A strategies to bridge revenue gaps caused by patent expirations, with a focus on acquiring late-stage or early-commercialization assets [10][12]. Private Equity and Investment Trends - The report notes a significant increase in private equity interest in life sciences suppliers, with a 50% growth in transaction volume and an 85% increase in transaction value, reaching $28.3 billion [19][20]. - The funding environment is becoming increasingly challenging, prompting many companies to seek alternative financing methods, including public-private partnerships [25][29]. Strategic Partnerships and Collaborations - The report emphasizes the growing trend of establishing partnerships and collaborations as an alternative to M&A, particularly for small to mid-sized biotech companies facing funding challenges [23][24]. - Companies are increasingly focusing on strategic alliances to leverage new technologies and capabilities, particularly in AI and machine learning [23][24].